Cytosorbents (CTSO) Net Income (QoQ) (2010 - 2026)
Cytosorbents (CTSO) Net Income (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.38 Bn | 176.08 Bn | 6.27 Bn |
| 2 | Stryker | 129.56 Bn | 126.68 Bn | 3.81 Bn |
| 3 | Medtronic | 109.00 Bn | 99.78 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.58 Bn | 43.90 Bn | 1.29 Bn |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 27.05 Bn | 26.48 Bn | - |
| 9 | Koninklijke Philips | 25.59 Bn | 22.46 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -169.79% |
| Dec 31, 2025 | -29.04% |
| Sep 30, 2025 | 87.42% |
| Jun 30, 2025 | -1,605.47% |
| Mar 31, 2025 | -135.57% |
| Dec 31, 2024 | 250.14% |
| Sep 30, 2024 | 35.55% |
| Jun 30, 2024 | 29.46% |
| Mar 31, 2024 | 0.75% |
| Dec 31, 2023 | 33.23% |
| Sep 30, 2023 | -39.19% |
| Jun 30, 2023 | 9.85% |
| Mar 31, 2023 | -855.77% |
| Dec 31, 2022 | 93.72% |
| Sep 30, 2022 | -12.15% |
| Jun 30, 2022 | -21.33% |
| Mar 31, 2022 | 3.66% |
| Dec 31, 2021 | -45.28% |
| Sep 30, 2021 | -36.96% |
| Jun 30, 2021 | -12.23% |